Cabaletta Bio Shares Spike 34% After Key RESET-PV Trial Milestone

Introduction

Cabaletta Bio Inc. (NASDAQ: CABA) is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania. The company applies its proprietary CABA® platform—focused on B cell ablation and engineered T cell therapies—to develop treatments for patients with autoimmune diseases. As of October 31, 2025, the share price stands at $3.32, reflecting a 34.41% increase, on a trading volume of 7,318,493 shares.

Corporate Structure and Experience

Founded in 2017, Cabaletta Bio employs between 51 and 200 staff across research, clinical development, and corporate functions. The company’s leadership includes executives with experience in cell and gene therapy commercialization, regulatory affairs, and manufacturing scale-up. Cabaletta operates its laboratories and offices in Philadelphia, utilizing both in-house capabilities and partnerships for clinical-stage manufacturing.

Biotechnology by Louis Reed

Recent Developments and News

On October 9, 2025, Cabaletta presented data from the RESET-PV Phase 1/2 trial in pemphigus vulgaris at the European Society of Gene & Cell Therapy conference in Sevilla, Spain. Key findings include:

• Complete peripheral B cell depletion in two of three patients without preconditioning chemotherapy.
• Improvements on the Pemphigus Disease Area Index one month after infusion.
• No reported cases of immune effector cell-associated neurotoxicity syndrome (ICANS) in this cohort.

Following the presentation, the share price increased from $2.40 to $3.25, and as of October 10, 2025, closed at $2.71. The company announced plans to expand enrollment in the RESET-PV trial and evaluate higher dosing regimens and no-preconditioning protocols across other RESET indications.

In November 2023, Cabaletta entered a Technology Adoption Partnership with manufacturing partner Cellares to assess the automated production of its lead candidate, CABA-201, on Cellares's Cell Shuttle™ platform. This collaboration aims to streamline cell therapy manufacturing and support future commercial-scale supply.

Financial and Strategic Analysis

As of October 29, 2025 (Yahoo Finance data):

• Market capitalization: $231.41 million
• Enterprise value: $61.62 million
• Beta (5-year monthly): 3.01
• Trailing net income (12 months): –$144.29 million
• Total cash (most recent quarter): $194.68 million
• Total debt/equity (most recent quarter): 13.95%
• Diluted EPS (TTM): –$2.71

Cabaletta’s cash runway is supported by its cash balance and strategic collaborations. The absence of product revenue highlights the clinical milestones ahead—particularly the advancement of CABA-201 (CD19-CAR T) through registrational pathways in systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis. The company holds FDA Fast Track Designations in dermatomyositis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, and multiple sclerosis, and an RMAT designation in myositis.

Market Position and Industry Context

Cabaletta operates in the segment of CAR T and engineered T cell therapies for autoimmune diseases, distinct from oncology-focused CAR T developers. The CABA® platform aims to reset immune tolerance and addresses unmet needs in chronic autoimmune conditions traditionally managed by lifelong immunosuppression. Competitors in this space include other cell therapy biotech firms exploring B cell–targeted or antigen-specific T cell approaches. The outcome of pivotal trials and advancements in scalable manufacturing will influence Cabaletta’s positioning against established biologics and small-molecule therapies in rheumatology and neurology.

tl;dr

Shares of Cabaletta Bio increased 34.41% on October 10, 2025, after data presented on October 9 at ESGCT indicated complete B cell depletion without preconditioning in the RESET-PV trial. Plans are in place to expand enrollment and adjust dosing. The company reported $194.68 million in cash as of Q3 2025, supporting Phase 1/2 trials for CABA-201 in multiple autoimmune indications, and collaborates with Cellares on automated manufacturing. Future catalysts include additional trial readouts and regulatory interactions toward potential registrational filings.